SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-027633
Filing Date
2023-03-02
Accepted
2023-03-02 07:05:17
Documents
14
Period of Report
2023-03-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm238265d1_8k.htm   iXBRL 8-K 26998
2 EXHIBIT 99.1 tm238265d1_ex99-1.htm EX-99.1 148019
6 GRAPHIC tm238265d1_ex99-1img01.jpg GRAPHIC 7167
  Complete submission text file 0001104659-23-027633.txt   380077

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA icpt-20230302.xsd EX-101.SCH 3054
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE icpt-20230302_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE icpt-20230302_pre.xml EX-101.PRE 22609
8 EXTRACTED XBRL INSTANCE DOCUMENT tm238265d1_8k_htm.xml XML 3498
Mailing Address 305 MADISON AVENUE MORRISTOWN NJ 07960
Business Address 305 MADISON AVENUE MORRISTOWN NJ 07960 646-747-1000
INTERCEPT PHARMACEUTICALS, INC. (Filer) CIK: 0001270073 (see all company filings)

IRS No.: 223868459 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35668 | Film No.: 23696385
SIC: 2834 Pharmaceutical Preparations